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Objectives: Asian and Pacific Islanders (APIs) constitute less than 6% of the US population, but 
account for more than half of Americans with chronic hepatitis B virus (HBV) infection. We 
sought to examine the effect of country of origin on HBV testing and chronic HBV infection 
prevalence among APIs.
Methods: We analyzed demographic and clinical data collected for adults from Kaiser 
Permanente Hawaii with 1 or more healthcare encounters during 2006 to 2008, 12 months or more 
of follow-up before 2009, and no HBV-related diagnosis within 6 months of enrollment. Persons 
who received a test and a positive test result for HBV surface antigen or HBV DNA were 
classified “tested” and with “chronic HBV infection”, respectively.
Results: Of 92,687 eligible APIs, 53,573 (58%) had country-of-origin data available. Among 
those, 41,263 were US born; 28.3% were tested; and 1.8% of those tested had chronic HBV 
infection. Of 12,310 foreign-born APIs, 30.5% were tested and 7.4% of those tested had chronic 
HBV infection. Foreign-born APIs had higher odds of being tested (odds ratio [OR] = 1.15) and 
testing positive (OR = 4.18) compared with US-born APIs. Persons with 2 or more abnormal tests 
for alanine aminotransferase (ALT) levels had higher odds of getting tested (OR = 6.12) and of 
testing positive (OR = 1.86) compared with persons with other ALT levels.
Conclusions: Less than one-third of this managed care API population (29% of 53,573) was 
tested, yet the prevalence of chronic HBV infection (3.2%) was 12 times higher than that of the 
general US population. These findings underscore the importance of adherence to HBV testing 
guidelines to identify persons with infection so they may be linked to care.
In the United States, between 800,000 and 2 million people live with chronic hepatitis B 
virus (HBV) infection and 2000 to 4000 deaths are attributed to HBV infection annually.1-4 
Cirrhosis and hepatocellular carcinoma (HCC) are 2 major long-term complications of 
chronic HBV infection that significantly increase morbidity and mortality. Asian and Pacific 
Islanders (APIs) make up less than 6% of the US population but account for more than half 
of Americans living with chronic HBV infection5,6; hepatocellular carcinoma (HCC) rates 
are highest among APIs, and HCC is a leading cause of cancer deaths in this population.7-9 
Most APIs with chronic HBV infection acquire their infection at birth through mother-to-
child transmission or during childhood.10
In 2009, an estimated 1.32 million foreign-born individuals with chronic HBV infection 
were thought to be living in the United States, and 58% of those persons migrated from 
Asia, where HBV infection is highly endemic.2 The population makeup of Hawaii, the 50th 
US state, includes 47% persons of Asian descent and 29% persons of Native Hawaiian/
Pacific Islander descent.5,11,12 Among Hawaii’s 212,229 foreign-born residents in 2000, 
73% were born in countries with endemic HBV infection, including China, Vietnam, the 
Philippines, and elsewhere among the South Pacific Islands.13
In Hawaii, Kaiser Permanente (KPHI) has approximately 220,000 members and is the 
largest health maintenance organization (HMO) providing care in the state.14 Commensurate 
with the high representation of APIs living in Hawaii, APIs constitute approximately half of 
KPHI’s membership. Given the unique demographic conditions in Hawaii relative to other 
US states, and our access to demographic and clinical data collected from patient 
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encounters, we sought to examine the effect of country of origin on HBV infection testing 
and prevalence among APIs at KPHI.
METHODS
Persons eligible for the study included those who: (1) were aged 18 years or older; (2) had at 
least 1 KPHI clinical encounter at any time during January 1, 2006, to December 31, 2008; 
and (3) completed at least 12 months of continuous follow-up any time before 2009. To 
examine HBV infection testing and prevalence among persons without previously diagnosed 
infection, we excluded those with any HBV-related International Classification of Diseases, 
Ninth Revision (ICD-9) diagnosis code within 6 months of their first KPHI clinical 
encounter. Retrospective electronic data were available through January 1, 1998.
Patient data were collected from electronic medical records and included age (as of last 
encounter before December 31, 2008), gender, race/ethnicity, annual income (derived from 
census tract data based on geocode), and serum alanine aminotransferase (ALT) level. 
Abnormal ALT was defined as a level higher than the lab-specific upper limit of normal 
value (range: 3-63 IU/L). Data were collected from the date of the patient’s earliest health 
plan enrollment through the last health plan encounter, ending December 31, 2008. Methods 
were identical to those used in an earlier analysis of hepatitis testing and prevalence among 
1.2 million persons in 4 healthcare organizations including KPHI, but which lacked country-
of-origin data.15 Briefly, persons were classified as “tested” if they had at least 1 test 
performed for HBV surface antigen (HBsAg) or a qualitative or quantitative test for HBV 
DNA; those classified with “HBV infection” had at least 1 positive result for any of these 
tests. The number of persons with infection divided by the number of persons tested was 
calculated to determine HBV infection prevalence. APIs were classified as foreign born 
(birth in Asian or Pacific Island countries) or US born (birth in the United States or Canada), 
based on the self-reported country of origin.
This study was reviewed and approved by the KPHI Institutional Review Board and 
followed guidelines of the US Department of Health and Human Services for protection of 
human subjects.
Statistical analysis was performed using SAS, version 9.2 (SAS Institute Inc, Cary, North 
Carolina). Chi-squared test (χ2) was used to ascertain differences in characteristics between 
US-born and foreign-born APIs.
RESULTS
Study Population
After exclusion of 198 persons with an HBV-related ICD-9 diagnosis code within 6 months 
of their first KPH clinical encounter, a total of 189,550 KPHI adults met the study inclusion 
criteria. Among eligible adults, 92,687 (48.9%) were APIs. Information on country of origin 
was available for 53,573 persons: 12,310 (23%) were born in Asian and Pacific Island 
countries and 41,263 (77%) were born in the United States (n = 41,235) or Canada (n = 28). 
Vijayadeva et al. Page 3
Am J Manag Care. Author manuscript; available in PMC 2019 May 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Among all APIs (N = 53,575), 29% (n = 15,439) were tested for HBV infection and, among 
those tested, 3.2% (n = 494) were infected.
The principal demographic and clinical characteristics of the US and foreign-born APIs are 
presented in Table 1. Compared with foreign-born APIs, US-born APIs were more likely to 
be younger than age 30 years or older than age 69 years. Foreign-born APIs were more 
likely to be female, to have lower annual incomes, and to have had at least 2 abnormal ALT 
test results before undergoing HBV infection testing. A greater proportion of foreign-born 
APIs were tested and a greater proportion had HBV infection compared with US-born APIs 
(tested: 3752 [30.5%] vs 11,687 [28.3%]; tested positive: 279 [7.4%] vs 215 [1.8%]). 
Among APIs with at least 2 abnormal ALT test results, 46% of foreign-born and 41% of US-
born were tested for HBV infection, 8.6% of foreign born and 1.9% of US-born were 
infected.
Table 2 show the important factors associated with odds of getting tested and testing positive 
for HBV infection. Individuals aged 30 to 39 years had higher odds of getting tested and of 
testing positive than other age groups. Females had higher odds of getting tested than males. 
Repeating the analysis excluding the pregnant women who were ever tested for HBsAg (n = 
7092), the odds ratio (OR) for females attenuated from 3.26 to 1.13 (data not shown). 
Foreign-born APIs had higher odds of being tested (OR = 1.15) and testing positive (OR = 
4.18) compared with US-born APIs. Persons with at least 2 or more abnormal ALT tests had 
higher odds of getting tested (OR = 6.12) and testing positive (OR = 1.86) compared with 
other ALT levels. Repeating the analysis with pregnant women excluding OR for foreign-
born APIs and ALT levels did not produce results that differed much.
Table 3 shows the proportion of foreign-born APIs who were tested and infected with HBV 
by country of birth. Among the 12,310 foreign-born APIs, 11,058 (89.8%) were from 
countries with high HBV endemicity (ie, HBsAg prevalence ≥8%)16; of these, 29.9% were 
tested for HBV infection and 7.9% of those were positive for HBV infection. The remaining 
10.2% of foreign-born APIs were from countries with intermediate HBV endemicity (ie, 
HBsAg prevalence 2%−7%)15; of these, 29.8% were tested and 2.7% were positive for HBV 
infection. Among all foreign-born APIs tested, the proportion of those infected ranged from 
2.7% (Japan) to 12.3% (China). Approximately 50% of the foreign-born APIs were from the 
Philippines; of these, 29.9% were tested and 5.5% were positive for HBV infection.
DISCUSSION
In this study of HBV testing and infection prevalence among APIs in a large HMO, we 
found that less than one-third of persons without a HBV diagnosis code at enrollment were 
tested for HBV infection. Among APIs who were tested, the prevalence of HBV infection 
(3.2%) was almost 12 times higher than that of the general US population (HB-sAg 
prevalence 0.27%). Among foreign-born APIs who were tested, 90% of whom were born in 
countries with high HBV endemicity, infection prevalence was largely commensurate with 
that of their country of origin (7.5% overall). These findings support US Centers for Disease 
Control and Prevention (CDC) guidelines that recommend HBV infection screening for 
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pregnant women, persons with high-risk behavior, and those born in Asia, Africa, and other 
geographic areas where HBsAg prevalence exceeds 2%.3
Even among US-born APIs, the prevalence of HBV infection was high (1.8%) relative to the 
general US population. Maternal country of birth information among US-born APIs might 
have permitted differentiation of first generation “API Americans” from those whose 
families had resided in the United States for multiple generations, and may have permitted 
further differentiation of infection prevalence; however, we did not have access to such 
information.
Results were compared with those from other studies. For example, a study by Lin et al 
reported HBV prevalence to be almost double (6.2%, 185 of 2973) that found in our study 
among previously undiagnosed API adults, and foreign-born APIs (10.7% HBsAg-positive 
test result) were approximately 20 times more likely to be chronically infected than US-born 
APIs (0.7% HBsAg-positive test result; RR 19.4, 95% CI, 2.6-141.8.17 Two other US-based 
studies—1 conducted in Hawaii (overall HBsAg prevalence, 3.6%)13 and another that used 
university students in California as study subjects (overall HBsAg prevalence of 2.3%, 1.4% 
in US-born and 3.3% in foreign-born APIs)18— assessed HBV infection prevalence, and 
results of those studies more closely aligned with our results, although these studies did not 
limit their analysis to APIs and had an age range of 18 to 21 years. In our study, perhaps 
most remarkable was that among APIs with a history of at least 2 abnormal ALT tests, fewer 
than 50% were tested for HBV infection. CDC and the American Association for the Study 
of Liver Diseases guidelines recommend testing persons with unexplained abnormal liver 
enzyme tests for HBV (and hepatitis C virus) infection.19
Our study had a number of limitations. In order to ensure assessment of persons with 
sustained followup, eligibility criteria for the study required at least 12 months of continuous 
follow-up any time before 2009. We acknowledge that some persons could have been tested 
in 2009 or thereafter and not included in our analysis. In addition, although we excluded 
those with an HBV ICD-9 diagnosis code within 6 months of their first clinical encounter, 
some persons could have previously tested negative for HBV infection or been vaccinated 
for HBV in another healthcare setting prior to our period of study, and might not need to be 
tested again. Secondly, from a case definition standpoint, we used a single HBsAg or HBV 
DNA to define testing for and infection with HBV. Although most of these infections were 
chronic, it is conceivable that some were actually acute. Given the low incidence of acute 
HBV infection in the United States, however, it is unlikely that such misclassification would 
have appreciably affected our results.
Finally, we recognize that the estimates of testing frequency and infection prevalence in our 
cohort are not necessarily reflective of all private and public healthcare systems in the 
United States. Nonetheless, our study had a large sample size and was conducted in a setting 
with high representation of persons of API descent.
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CONCLUSIONS
In summary, we found that less than one-third of this API population in managed care were 
tested for HBV infection and that among those tested, the prevalence of HBV infection was 
nearly 12 times higher than that of the overall US population. Infection prevalence among 
foreign-born APIs was similar to that of their country of origin. The prevalence of HBV 
infection among US-born APIs was almost 7 times higher than for the overall US 
population. These findings underscore the importance of adherence to current US guidelines 
that recommend HBV testing of persons born in countries with intermediate and high HBV 
endemicity, and the testing of US-born persons whose parents were born in such countries. 
At KPHI, country-of-birth information is not collected routinely. The results of this paper 
might provide evidence of the importance of collecting such information routinely in our 
health system. Sensitivity analysis has shown the cost-effectiveness of HBV screening, even 
with the prevalence of chronic HBV infection as low as 1%,20 and hence it is important to 
focus HBV screening efforts on high-prevalence groups such as foreign-born APIs. Persons 
found to be susceptible to infection should be vaccinated, and those found to have infection 
should be evaluated for treatment.
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Take-Away Points
Hepatitis B virus (HBV) infection prevalence among foreign-born Asian and Pacific 
Islanders (APIs) living in the United States was similar to that found in their country of 
origin.The prevalence of HBV infection among US-born APIs was almost 7 times higher 
than it was for the overall US population. These findings underscore the importance of 
adherence to current US guidelines that recommend HBV testing of persons born in 
countries with intermediate and high HBV endemicity, and the testing of US-born 
persons whose parents were born in such countries. Persons found to be susceptible to 
infection should be vaccinated, and those found to have infection should be evaluated for 
treatment.
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